Novo Nordisk has completed the acquisition of Catalent, a strategic move that will allow it to strengthen the production of Wegovy, its successful weight loss medication. The operation, which was announced in February 2024, has been completed with an investment of 10.659 billion euros.
Can you imagine leading a network of autonomous teams instead of a hierarchical pyramid?
The Second After Work of Corporate Rebels - Mexico Rebel Cell is your opportunity to discover how the most innovative companies are breaking away from the traditional leadership model. This March 31, 2025 at 6:30 pm (Mexico City time), be part of a unique conversation about how to evolve from a hierarchical structure to a network of teams with autonomy, collaboration and agility.
What will you learn?
- Organizational transformation: From the hierarchical pyramid to the network of teams.
- Distributed leadership: Empowering teams for agile decision-making.
- Collaboration culture: How to eliminate silos and accelerate innovation.
This event is designed for HR leaders, Change Management directors and decision makers who want to take organizational agility to the next level. Reserve your spot now and join the movement that is redefining the future of work! 🚀
The agreement includes the acquisition of three production plants that, according to Lars Fruergaard Jørgensen, president and CEO of Novo Nordisk, will allow the Danish company to "expand production capacity with greater scale and speed".
Although the European Union had promised a verdict before December 6, the approval was delayed a few days, but came in time for Novo Nordisk to start 2025 with the operation closed. The acquisition is part of the pharmaceutical company's strategy to respond to the high demand for Wegovy, a drug that has significantly boosted the company's value, consolidating it as the most valuable in Europe.
The operation was not without controversy. Rival companies such as Roche and Eli Lilly expressed their opposition, accusing Novo Nordisk of unfair competition practices and asking authorities to stop the acquisition. However, the operation went ahead.
In parallel, Novo Nordisk has announced the opening of a new plant in Denmark, for which it will invest 1.140 billion euros. This new facility will be focused on the development of medications for rare diseases, further expanding its production and innovation capacity in new treatments.
In financial terms, Novo Nordisk closed the third quarter of 2024 with revenues of 2.313 billion dollars, which represents an increase of 48% compared to the same period last year. This growth was driven mainly by Wegovy sales, which has become one of the pharmaceutical company's most demanded products.
With this acquisition, Novo Nordisk strengthens its leading position in the obesity and weight loss market, and prepares to face competition in a market that continues to boom.
Do you have a team of communicators and need them to become Rockstars?
Storytelling Rockstars is a step-by-step guide that will allow you to transform your KOLs, Commercial Staff and Rising Leaders into Inspiring Communicators in just 4 steps. Best of all, it has no cost! - Download it here.